J Raffel1, A R Gafson2, O Malik2, R Nicholas2. 1. Department of Medicine, Imperial College London, UK joelraffel@doctors.org.uk. 2. Department of Medicine, Imperial College London, UK.
Abstract
BACKGROUND: Anti-JC virus antibody status is a risk factor for progressive multifocal leukoencephalopathy after natalizumab treatment in multiple sclerosis. Previous studies have used a cross-sectional approach to conclude that the presence and duration of natalizumab treatment does not influence anti-JCV Ab seropositivity. OBJECTIVES: Using a longitudinal approach, we measured change in anti-JCV Ab results after natalizumab treatment. METHODS: Anti-JCV Ab results (n = 1154) from the second-generation STRATIFY JCV™ DxSelect™ test were analysed from an observational cohort of MS patients on natalizumab (n = 485; n = 340 with repeat testing; n = 657 repeat tests on natalizumab). RESULTS: Across sequential paired tests, seroconversion rate was greater than seroreversion rate (40/364 (11.0%) versus 18/293 (6.1%); p < 0.05). Moreover, anti-JCV Ab index increased across longitudinal paired tests (mA-B 0.102; paired t(656) = 5.0; p < 0.0001). This magnitude of Ab level increase far exceeds that expected due to increasing age alone. CONCLUSION: Our data suggest that natalizumab therapy is associated with a significant and substantial increase in anti-JCV Ab index over time. Further work should focus on the underlying mechanisms of this phenomenon, and the clinical relevance to risk stratification.
BACKGROUND: Anti-JC virus antibody status is a risk factor for progressive multifocal leukoencephalopathy after natalizumab treatment in multiple sclerosis. Previous studies have used a cross-sectional approach to conclude that the presence and duration of natalizumab treatment does not influence anti-JCV Ab seropositivity. OBJECTIVES: Using a longitudinal approach, we measured change in anti-JCV Ab results after natalizumab treatment. METHODS: Anti-JCV Ab results (n = 1154) from the second-generation STRATIFY JCV™ DxSelect™ test were analysed from an observational cohort of MSpatients on natalizumab (n = 485; n = 340 with repeat testing; n = 657 repeat tests on natalizumab). RESULTS: Across sequential paired tests, seroconversion rate was greater than seroreversion rate (40/364 (11.0%) versus 18/293 (6.1%); p < 0.05). Moreover, anti-JCV Ab index increased across longitudinal paired tests (mA-B 0.102; paired t(656) = 5.0; p < 0.0001). This magnitude of Ab level increase far exceeds that expected due to increasing age alone. CONCLUSION: Our data suggest that natalizumab therapy is associated with a significant and substantial increase in anti-JCV Ab index over time. Further work should focus on the underlying mechanisms of this phenomenon, and the clinical relevance to risk stratification.
Authors: Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili Journal: Rev Med Virol Date: 2015-12-14 Impact factor: 6.989
Authors: Harald Hegen; Michael Auer; Gabriel Bsteh; Franziska Di Pauli; Tatiana Plavina; Janette Walde; Florian Deisenhammer; Thomas Berger Journal: PLoS One Date: 2017-03-20 Impact factor: 3.240
Authors: Harald Hegen; Janette Walde; Gabriel Bsteh; Michael Auer; Sebastian Wurth; Anne Zinganell; Franziska Di Pauli; Florian Deisenhammer; Thomas Berger Journal: Front Immunol Date: 2018-10-25 Impact factor: 7.561
Authors: Nicholas Schwab; Tilman Schneider-Hohendorf; Béatrice Pignolet; Johanna Breuer; Catharina C Gross; Kerstin Göbel; David Brassat; Heinz Wiendl Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-01-27
Authors: C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young Journal: J Neurol Neurosurg Psychiatry Date: 2015-10-22 Impact factor: 10.154